Description of Research Expertise

Dr. Sarkar’s research focuses on immune-mediated thrombotic disorders, particularly Antiphospholipid Syndrome (APS) and it's thromboinflammatory and obstetrics complications, Thrombotic Thrombocytopenic Purpura (TTP), and Adenivirus-Induced Immune Thrombotic Thrombocytopenia (AITT). She integrates in vivo and in vitro models to study Thrombo-inflammation and develop novel, non-anticoagulant therapies.

She has established a range of animal models—spanning thrombosis, sepsis, pregnancy model, arthritis, and diabetes—and investigates key drivers of disease such as complement activation, NET formation, and PF4:β2GPI complex-mediated thrombosis. In parallel, she utilizes human and rodent primary cell systems and microfluidic assays to in vitro thrombosis model using patient-derived plasma or plasma derived IgGs.

Her current work is centered on dissecting the role of PF4:NET:β2GPI interactions in APS and TTP, with a further focus on their unexplored connection to complement activation. She also applies nanotechnology and antibody engineering to explore targeted therapeutic strategies.

Through this integrated approach, Dr. Sarkar aims to define the molecular links between thrombosis, immunity, and inflammation to advance precision therapies for autoimmune thrombotic diseases.